Favipiravir
- Generic Name
- Favipiravir
- Brand Names
- -
- Drug Type
- Small Molecule
- Chemical Formula
- C5H4FN3O2
- CAS Number
- 259793-96-9
- Unique Ingredient Identifier
- EW5GL2X7E0
- Background
Discovered by Toyama Chemical Co., Ltd. in Japan, favipiravir is a modified pyrazine analog that was initially approved for therapeutic use in resistant cases of influenza. The antiviral targets RNA-dependent RNA polymerase (RdRp) enzymes, which are necessary for the transcription and replication of viral genomes.
...
- Indication
⑴用于埃博拉病毒感染的治疗。
⑵用于治疗成人新型或再次流行的流感（仅限于其他抗流感病毒药物治疗无效或效果不佳时使用）
- Associated Conditions
- Treatment resistant Novel Influenza, Treatment resistant Reemerging Influenza
- Associated Therapies
- -
Clinical Trial For Early SARS-CoV-2 (COVID-19) Treatment
- Conditions
- Interventions
- First Posted Date
- 2021-07-29
- Last Posted Date
- 2021-07-29
- Lead Sponsor
- Health Institutes of Turkey
- Target Recruit Count
- 1120
- Registration Number
- NCT04981379
- Locations
- 🇹🇷
Ankara City Hospital, Ankara, Turkey
🇹🇷Istanbul University Istanbul Medicine Faculty, Istanbul, Turkey
🇹🇷Sancaktepe Şehit Prof. Dr. İlhan Varank Training and Research Hospital, Istanbul, Turkey
Favipiravir +/- Nitazoxanide: Early Antivirals Combination Therapy in COVID-19
- Conditions
- Interventions
- First Posted Date
- 2021-06-09
- Last Posted Date
- 2023-03-24
- Lead Sponsor
- Coordinación de Investigación en Salud, Mexico
- Target Recruit Count
- 120
- Registration Number
- NCT04918927
- Locations
- 🇲🇽
Hospital de Infectología "Daniel Méndez Hernández" del Centro Médico Nacional La Raza, Ciudad de Mexico, Azcapotzalco, Mexico
Pharmacokinetics, Tolerability and Safety of Favipiravir Compared to Ribavirin for the Treatment of Lassa Fever
- First Posted Date
- 2021-06-01
- Last Posted Date
- 2023-02-08
- Lead Sponsor
- Bernhard Nocht Institute for Tropical Medicine
- Target Recruit Count
- 40
- Registration Number
- NCT04907682
- Locations
- 🇳🇬
Federal Medical Center of Owo, Owo, Ondo State, Nigeria
🇳🇬Irrua Specialist Teaching Hospital, Irrua, Edo State, Nigeria
Efficacy and Safety of Favipiravir and Ribavirin Formulation for Treatment of COVID-19
- First Posted Date
- 2021-04-02
- Last Posted Date
- 2021-04-02
- Target Recruit Count
- 100
- Registration Number
- NCT04828564
- Locations
- 🇹🇷
Ankara University, School of Medicine, Ankara, Cebeci, Turkey
🇹🇷Umraniye Training and Research Hospital, Istanbul, Turkey
🇹🇷Koc University Hospital, Istanbul, Turkey
Favipiravir in High-risk COVID-19 Patients
- First Posted Date
- 2021-03-26
- Last Posted Date
- 2021-11-24
- Lead Sponsor
- Penang Hospital, Malaysia
- Target Recruit Count
- 500
- Registration Number
- NCT04818320
- Locations
- 🇲🇾
Penang General Hospital, George Town, Pulau Pinang, Malaysia
Trial to Determine the Efficacy/Safety of Plitidepsin vs Control in Patients With Moderate COVID-19 Infection
- Conditions
- Interventions
- First Posted Date
- 2021-03-05
- Last Posted Date
- 2023-03-09
- Lead Sponsor
- PharmaMar
- Target Recruit Count
- 205
- Registration Number
- NCT04784559
- Locations
- 🇧🇷
Hospital Felicio Rocho, Belo Horizonte, MG, Brazil
🇲🇽Universidad Autonoma de Nuevo Leon - Hospital Universitario "Dr. Jose Eleuterio Gonzalez", Monterrey, NL, Mexico
🇷🇴Institutul National De Boli Infectioase "Prof. Dr. Matei Bals", Bucharest, Romania
AGILE (Early Phase Platform Trial for COVID-19)
- First Posted Date
- 2021-02-09
- Last Posted Date
- 2024-11-19
- Lead Sponsor
- University of Liverpool
- Target Recruit Count
- 600
- Registration Number
- NCT04746183
- Locations
- 🇬🇧
Manchester University NHS Foundation Trust, Manchester, United Kingdom
🇿🇦Desmond Tutu Health Foundation, Cape Town, South Africa
🇿🇦Ezintsha, Johannesburg, South Africa
Antiviral Drugs on the Treatment of SARS-CoV-2
- Conditions
- Interventions
- First Posted Date
- 2021-01-27
- Last Posted Date
- 2023-08-02
- Lead Sponsor
- Astana Medical University
- Target Recruit Count
- 150
- Registration Number
- NCT04727775
- Locations
- 🇰🇿
Semey Medical University, Semey, Kazakhstan
🇰🇿Aidos Konkaev, Astana, Kazakhstan
Management of Cytokine Storms in Severe COVID-19 Patients With Autologous Activated Platelet-rich Plasma Therapy
- First Posted Date
- 2021-01-20
- Last Posted Date
- 2021-01-20
- Lead Sponsor
- Hayandra Peduli Foundation
- Target Recruit Count
- 30
- Registration Number
- NCT04715360
- Locations
- 🇮🇩
Koja Regional Public Hospital, Jakarta, DKI Jakarta, Indonesia
Efficacy of Favipiravir in Treatment of Mild & Moderate COVID-19 Infection in Nepal
- First Posted Date
- 2021-01-05
- Last Posted Date
- 2021-01-05
- Lead Sponsor
- Nepal Health Research Council
- Target Recruit Count
- 676
- Registration Number
- NCT04694612
- Locations
- 🇳🇵
Charak Memorial Hospital, Pokhara, Gandaki, Nepal
🇳🇵Armed Police Force Hospital, Kathmandu, Bagmati, Nepal
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.